Nonalcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is accumulated in the liver without alcohol consumption. NAFLD is the most common liver disorder in advanced countries. NAFLD is a spectrum of pathology involving hepatic steatosis with/without inflammation and nonalcoholic steatohepatitis with accumulation of hepatocyte damage and hepatic fibrosis. Recent studies have revealed that NAFLD results in the progression of cryptogenic cirrhosis that leads to hepatocarcinoma and cardiovascular diseases such as heart failure. The main causes of NAFLD have not been revealed yet, metabolic syndromes including obesity and insulin resistance are widely accepted for the critical risk factors for the pathogenesis of NAFLD. Nuclear receptors (NRs) are transcriptional factors that sense environmental or hormonal signals and regulate expression of genes, involved in cellular growth, development, and metabolism. Several NRs have been reported to regulate genes involved in energy and xenobiotic metabolism and inflammation. Among various NRs, farnesoid X receptor (FXR) is abundantly expressed in the liver and a key regulator to control various metabolic processes in the liver. Recent studies have shown that NAFLD is associated with inappropriate function of FXR. The impact of FXR transcriptional activity in NAFLD is likely to be potential therapeutic strategy, but still requires to elucidate underlying potent therapeutic mechanisms of FXR for the treatment of NAFLD. This article will focus the physiological roles of FXR and establish the correlation between FXR transcriptional activity and the pathogenesis of NAFLD.

Citations

Citations to this article as recorded by  

• Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
  Hongshan Li, Yingfei Xi, Xin Xin, Qin Feng, Yiyang Hu
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer
  Yanguang Hou, Jiachen Liu, Shiyu Huang, Lei Wang, Juncheng Hu, Xiuheng Liu
  Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
• Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
  Chander K. Negi, Pavel Babica, Lola Bajard, Julie Bienertova-Vasku, Giovanni Tarantino
  Metabolism.2022; 126: 154925.     CrossRef
• FXR: structures, biology, and drug development for NASH and fibrosis diseases
  Si-yu Tian, Shu-ming Chen, Cheng-xi Pan, Yong Li
  Acta Pharmacologica Sinica.2022; 43(5): 1120.     CrossRef
• Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
  Aamir Bashir, Ajay Duseja, Arka De, Manu Mehta, Pramil Tiwari
  Liver Research.2022; 6(2): 72.     CrossRef
• The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice
  Jamal Nasser Saleh Al-maamari, Mahardian Rahmadi, Sisca Melani Panggono, Devita Ardina Prameswari, Eka Dewi Pratiwi, Chrismawan Ardianto, Santhra Segaran Balan, Budi Suprapti
  Journal of Basic and Clinical Physiology and Pharmacology.2021; 32(4): 637.     CrossRef
• Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice
  Wen-Cong Li, Su-Xian Zhao, Wei-Guang Ren, Yu-Guo Zhang, Rong-Qi Wang, Ling-Bo Kong, Qing-Shan Zhang, Yue-Min Nan
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis
  Hongshan Li, Yingfei Xi, Xin Xin, Huajie Tian, Yiyang Hu
  Nutrition & Metabolism.2020;[Epub]     CrossRef
• Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
  Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
  Pharmacological Research.2020; 159: 104984.     CrossRef
• Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up‐Regulating Small Heterodimer Partner in Kupffer Cells
  Dan Jin, Tianfei Lu, Ming Ni, Han Wang, Jiang Zhang, Chenpeng Zhong, Chuan Shen, Jun Hao, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski, Jianjun Zhang, Ning Xu, Yuan Zhai
  Hepatology Communications.2020; 4(4): 540.     CrossRef
• Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota–bile acid–farnesoid X receptor axis
  Hongshan Li, Yingfei Xi, Xin Xin, Huajie Tian, Yiyang Hu
  Biomedicine & Pharmacotherapy.2020; 124: 109915.     CrossRef
• An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
  Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li
  BioMed Research International.2020; 2020: 1.     CrossRef
• Intestinal Barrier Function–Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota
  Yizhe Cui, Qiuju Wang, Renxu Chang, Xiaocui Zhou, Chuang Xu
  Journal of Agricultural and Food Chemistry.2019; 67(10): 2754.     CrossRef
• A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters
  Mao-xu Ge, Wei-xiao Niu, Jin-feng Ren, Shi-ying Cai, Dong-ke Yu, Hong-tao Liu, Na Zhang, Yi-xuan Zhang, Yu-cheng Wang, Rong-guang Shao, Ju-xian Wang, Hong-wei He
  Acta Pharmacologica Sinica.2019; 40(7): 895.     CrossRef
• Consenso mexicano de la enfermedad por hígado graso no alcohólico
  R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrer
  Revista de Gastroenterología de México.2019; 84(1): 69.     CrossRef
• Fish oil alleviates circadian bile composition dysregulation in male mice with NAFLD
  Yang Liu, Qi Li, Hualin Wang, Xiuju Zhao, Na Li, Hongyu Zhang, Guoxun Chen, Zhiguo Liu
  The Journal of Nutritional Biochemistry.2019; 69: 53.     CrossRef
• Effects of sanshoamides and capsaicinoids on plasma and liver lipid metabolism in hyperlipidemic rats
  Zhaojun Chen, Yongxiang Liu, Hui Wang, Zhongai Chen, Jia Liu, Hui Liu
  Food Science and Biotechnology.2019; 28(2): 519.     CrossRef
• The Mexican consensus on nonalcoholic fatty liver disease
  R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrer
  Revista de Gastroenterología de México (English Edition).2019; 84(1): 69.     CrossRef
• Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study
  Ning Liu, Jiao Feng, Yang Lv, Qing Liu, Jingfan Deng, Yujing Xia, Chuanyong Guo, Yingqun Zhou
  Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
• Essential role of nuclear receptors for the evaluation of the benefits of bioactive herbal extracts on liver function
  Fengling Wang, Yifan Wu, Xiaoting Xie, Jing Sun, Weidong Chen
  Biomedicine & Pharmacotherapy.2018; 99: 798.     CrossRef
• Maternal obesity has sex‐dependent effects on insulin, glucose and lipid metabolism and the liver transcriptome in young adult rat offspring
  Consuelo Lomas‐Soria, Luis A. Reyes‐Castro, Guadalupe L. Rodríguez‐González, Carlos A. Ibáñez, Claudia J. Bautista, Laura A. Cox, Peter W. Nathanielsz, Elena Zambrano
  The Journal of Physiology.2018; 596(19): 4611.     CrossRef
• Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/AMPK signaling pathway in vivo
  Lingli Zheng, Lianhong Yin, Lina Xu, Yan Qi, Hua Li, Youwei Xu, Xu Han, Kexin Liu, Jinyong Peng
  Biomedicine & Pharmacotherapy.2018; 97: 481.     CrossRef
• New therapeutic perspectives in non-alcoholic steatohepatitis
  Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
  Gastroenterología y Hepatología (English Edition).2018; 41(2): 128.     CrossRef
• Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
  Valerio Nobili, Anna Alisi, Antonella Mosca, Claudia Della Corte, Silvio Veraldi, Rita De Vito, Cristiano De Stefanis, Valentina D'Oria, Joerg Jahnel, Evelyn Zohrer, Eleonora Scorletti, Christopher D. Byrne
  Liver International.2018; 38(2): 342.     CrossRef
• The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives
  Stefano Gitto, Valeria Guarneri, Alessandro Sartini, Pietro Andreone
  Expert Review of Gastroenterology & Hepatology.2018; 12(2): 165.     CrossRef
• Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR
  Verena Hiebl, Angela Ladurner, Simone Latkolik, Verena M. Dirsch
  Biotechnology Advances.2018; 36(6): 1657.     CrossRef
• Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica
  Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
  Gastroenterología y Hepatología.2018; 41(2): 128.     CrossRef
• Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
  Qinwei Yu, Zhenzhou Jiang, Luyong Zhang
  Pharmacology & Therapeutics.2018; 190: 81.     CrossRef
• Hippocampal FXR plays a role in the pathogenesis of depression: A preliminary study based on lentiviral gene modulation
  Wei-Guan Chen, Jia-Xuan Zheng, Xi Xu, Yu-Ming Hu, Yu-Min Ma
  Psychiatry Research.2018; 264: 374.     CrossRef
• Bile acid receptors and the kidney
  Michal Herman-Edelstein, Talia Weinstein, Moshe Levi
  Current Opinion in Nephrology and Hypertension.2018; 27(1): 56.     CrossRef
• Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver
  Amir Hajighasem, Parvin Farzanegi, Zohreh Mazaheri, Marjan Naghizadeh, Ghoncheh Salehi
  PeerJ.2018; 6: e5522.     CrossRef
• Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
  Marco Poeta, Luca Pierri, Pietro Vajro
  Children.2017; 4(8): 66.     CrossRef
• Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
  S Singh, KK Kharbanda
  Archives of Hepatitis Research.2017; 3(1): 029.     CrossRef

Citations

Citations to this article as recorded by  

• Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
  Ting-ying Jiao, Yuan-di Ma, Xiao-zhen Guo, Yun-fei Ye, Cen Xie
  Acta Pharmacologica Sinica.2022; 43(5): 1103.     CrossRef
• Loperamide induces excessive accumulation of bile acids in the liver of mice with different diets
  Zili Lei, Hedong Rong, Yanhong Yang, Siping Yu, Tianle Zhang, Lei Chen, Ya Nie, Qi Song, Qing Hu, Jiao Guo
  Toxicology.2022; 477: 153278.     CrossRef
• Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms
  Giuseppe Ferrandino, Rachel R. Kaspari, Olga Spadaro, Andrea Reyna-Neyra, Rachel J. Perry, Rebecca Cardone, Richard G. Kibbey, Gerald I. Shulman, Vishwa Deep Dixit, Nancy Carrasco
  Proceedings of the National Academy of Sciences.2017;[Epub]     CrossRef